Silver Book

Silver Book Fact

Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly

Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.

Silber, Jeffrey H., Paul R. Rosenbaum, Martha E. Trudeau, Wei Chen, Xuernei Zhang, Scott A. Lorch, Rachel Rapaport Kelz, Rachel E. Mosher, and Orit Even-Shosan. Preoperative Antibiotics and Mortality in the Elderly. Ann Surg. 2005; 242(1): 107-14. http://journals.lww.com/annalsofsurgery/Abstract/2005/07000/Preoperative_Antibiotics_and_Mortality_in_the.15.aspx

Reference

Title
Preoperative Antibiotics and Mortality in the Elderly
Publication
Ann Surg
Publication Date
2005
Authors
Silber, Jeffrey H., Paul R. Rosenbaum, Martha E. Trudeau, Wei Chen, Xuernei Zhang, Scott A. Lorch, Rachel Rapaport Kelz, Rachel E. Mosher, and Orit Even-Shosan
Volume & Issue
Volume 242, Issue 1
Pages
107-14
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Publications

Healthcare-Associated Infections Factsheet

 https://www.silverbook.org/wp-content/uploads/2015/06/Screen-Shot-2015-06-30-at-3.02.28-PM.png Thumbnail

Related Facts

  • Reduction of central-line infections saved ~ 1,800 lives and $280 million
    Standardization of best practice interventions reduced central line-associated blood stream infections and saved an estimated 1,800 lives and $280 million.  
  • Pre-surgery antibiotic use reduces 6-day mortality by 50% in elderly
    Effective pre-surgery antibiotic use can reduce 60-day mortality in the elderly by 50%.  
  • Only a 20% reduction in drug-resistant infections would save $3.2 – $5.2 billion each year
    A 20% reduction in drug-resistant infections would save between 5.7 and 11.3 million additional hospital days and between $3.2 and $5.2 billion in healthcare costs, each year.  
  • Reduction in hospital-acquired HAIs could produce significant savings
    Practices that lead to a 20% reduction in preventable hospital-acquired HAIs would save up to $6.8 billion in medical costs. a 70% reduction would lead to a savings of up…  
  • Negative value of antibiotics to drug companies
    The value of an antibiotic to a drug company is negative $50 million- compared to the positive value of $1 billion for a new musculoskeletal drug.